---
title: "CRWS: Fiscal 2026 saw a return to profitability on lower sales, steady margins, and ongoing tariff risks"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290684130.md"
description: "Net sales declined 5.7% to $82.3M in fiscal 2026, with net income rebounding to $1.8M from a prior year loss, aided by insurance proceeds and absence of goodwill impairment. Gross margin held steady at 24.4%, but customer concentration, tariff uncertainty, and macroeconomic pressures remain key risks.Original document: Crown Crafts, Inc. [CRWS] SEC 10-K Annual Report — Jun. 24 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-06-24T11:07:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290684130.md)
  - [en](https://longbridge.com/en/news/290684130.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290684130.md)
---

# CRWS: Fiscal 2026 saw a return to profitability on lower sales, steady margins, and ongoing tariff risks

Net sales declined 5.7% to $82.3M in fiscal 2026, with net income rebounding to $1.8M from a prior year loss, aided by insurance proceeds and absence of goodwill impairment. Gross margin held steady at 24.4%, but customer concentration, tariff uncertainty, and macroeconomic pressures remain key risks.

Original document: Crown Crafts, Inc. \[CRWS\] SEC 10-K Annual Report — Jun. 24 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CRWS.US](https://longbridge.com/en/quote/CRWS.US.md)

## Related News & Research

- [ISS: Q2 2026 delivered 8.9% organic growth, 4.6% margin, and strong cash flow, with 2026 guidance reaffirmed](https://longbridge.com/en/news/295489259.md)
- [KMDA: Record-high revenue and profit growth in H1 and Q2 2026, with 2026 guidance reaffirmed](https://longbridge.com/en/news/295655423.md)
- [INR: Q2 2026 delivered record production, margin, and capital efficiency, with robust 2026 growth outlook](https://longbridge.com/en/news/295449560.md)
- [AQST: Q2 2026 revenue up 38% to $13.8M; Anaphylm NDA resubmission on track for Q3 2026](https://longbridge.com/en/news/295573837.md)
- [RXT: Q2 2026 revenue grew 0.6% to $670M; net loss widened to $68M; FY 2026 revenue guided at $2.45–$2.55B](https://longbridge.com/en/news/295454040.md)